Barbara Burtness
#142,397
Most Influential Person Now
American internist and oncologist
Barbara Burtness's AcademicInfluence.com Rankings
Barbara Burtnessphilosophy Degrees
Philosophy
#8182
World Rank
#11512
Historical Rank
Logic
#5212
World Rank
#6594
Historical Rank
Download Badge
Philosophy
Why Is Barbara Burtness Influential?
(Suggest an Edit or Addition)According to Wikipedia, Barbara Ann Burtness is an American internist and oncologist. She is a Anthony N. Brady Professor of Medicine at Yale University and Chief Translational Research Officer at Yale Cancer Center. She is co-director of the Stand Up to Cancer Fanconi Anemia Research Fund-Farrah Fawcett Foundation Head and Neck Cancer Research Team.
Barbara Burtness's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019) (1244)
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. (2016) (1199)
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study (2019) (871)
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study (2019) (871)
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. (2016) (860)
- Head and neck squamous cell carcinoma (2020) (762)
- Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. (2000) (759)
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial (2019) (716)
- Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. (2005) (714)
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort (2016) (651)
- NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. (2018) (381)
- E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. (2017) (335)
- The changing therapeutic landscape of head and neck cancer (2019) (327)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (2019) (327)
- NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. (2017) (285)
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 (2018) (277)
- Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis (2005) (275)
- Head and neck cancers. (2011) (262)
- Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. (2005) (238)
- Head and Neck Cancers, Version 1.2015. (2015) (186)
- Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. (2013) (185)
- Head and neck cancers: Clinical practice guidelines in oncology (2011) (178)
- Immunotherapy for head and neck cancer: Recent advances and future directions. (2019) (158)
- Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. (2013) (147)
- Head and Neck Cancers, Version 2.2014 (2014) (145)
- Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. (2000) (133)
- Head and Neck Cancers, Version 2.2013 (2013) (132)
- A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. (2014) (130)
- KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2018) (128)
- Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. (2003) (126)
- Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era (2003) (126)
- Defining Venous Involvement in Borderline Resectable Pancreatic Cancer (2010) (126)
- NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. (2009) (125)
- Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. (2014) (114)
- Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. (2015) (112)
- Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2019) (111)
- Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks (2018) (110)
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group. (2016) (109)
- Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. (2015) (107)
- The prognostic value of extranodal extension in human papillomavirus‐associated oropharyngeal squamous cell carcinoma (2017) (100)
- Treatment de-intensification strategies for head and neck cancer. (2016) (98)
- Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. (2005) (98)
- Phase III trial comparing cisplatin (C) + placebo (P) + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC) (2002) (94)
- Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. (2004) (94)
- Psychological functioning of caregivers for head and neck cancer patients. (2012) (94)
- TRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma (2017) (86)
- The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. (2008) (86)
- p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary (2014) (86)
- The role of cetuximab in the treatment of squamous cell cancer of the head and neck (2005) (81)
- Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. (2013) (80)
- Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer (2007) (79)
- LBA45_PRPembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial (2017) (76)
- Targeting EGFR resistance networks in head and neck cancer. (2009) (76)
- Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer (2010) (75)
- Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311) (2021) (72)
- Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. (2014) (72)
- Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. (2013) (71)
- Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma. (2019) (70)
- CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. (2016) (70)
- Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). (2020) (69)
- Vascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarray (2006) (68)
- APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma (2019) (67)
- Total-body echo-planar MR imaging in the staging of breast cancer: comparison with conventional methods--early experience. (1999) (66)
- Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients (2010) (64)
- Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer (2017) (64)
- Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. (2001) (62)
- Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis (2010) (61)
- A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma (2015) (61)
- Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. (2013) (60)
- Aurora kinases in head and neck cancer. (2013) (60)
- CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. (2010) (59)
- E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). (2014) (58)
- Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. (2015) (55)
- Postchemotherapy MRI Overestimates Residual Disease Compared with Histopathology in Responders to Neoadjuvant Therapy for Locally Advanced Breast Cancer (2006) (55)
- Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option (1999) (53)
- Proposing prognostic thresholds for lymph node yield in clinically lymph node‐negative and lymph node‐positive cancers of the oral cavity (2016) (53)
- Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma (2011) (52)
- Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. (2015) (52)
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012. (2016) (50)
- Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. (2019) (50)
- Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome (2007) (48)
- Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC) (2014) (47)
- Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). (2017) (45)
- Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting (2017) (45)
- Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. (1997) (45)
- Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck (2019) (44)
- A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma (2017) (44)
- Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). (2014) (43)
- Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. (2019) (42)
- Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base (2016) (42)
- Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy (2009) (42)
- A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). (2016) (42)
- Pregnancy‐Associated Breast Cancer (2005) (41)
- Correlates and Determinants of Nuclear Epidermal Growth Factor Receptor Content in an Oropharyngeal Cancer Tissue Microarray (2008) (41)
- Applications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas (2020) (41)
- EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer (2016) (41)
- Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303) (2007) (40)
- Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. (1998) (40)
- Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma (2011) (39)
- NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis (2017) (39)
- Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. (1998) (39)
- Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer (2017) (38)
- In vitro collection and posttransfusion engraftment characteristics of MNCs obtained by using a new separator for autologous PBPC transplantation (2000) (38)
- Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer (2014) (37)
- Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. (2018) (37)
- Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC) (2018) (37)
- Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. (2009) (37)
- Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma (2006) (37)
- Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. (2007) (36)
- Dysplasia at the margin? Investigating the case for subsequent therapy in 'low-risk' squamous cell carcinoma of the oral tongue. (2013) (36)
- Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer (2020) (36)
- Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. (2011) (35)
- An epidermal growth factor receptor chimeric human-murine monoclonal antibody (2005) (35)
- Trends and variations in the use of adjuvant therapy for patients with head and neck cancer (2014) (34)
- A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck (2011) (34)
- Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. (2014) (33)
- Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer. (2012) (33)
- Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer (2007) (33)
- HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes (2018) (33)
- A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. (2008) (32)
- Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303 (2014) (31)
- Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database (2018) (31)
- Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2016) (31)
- Oncology and hematology. (1995) (31)
- Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 (2014) (31)
- Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. (2016) (30)
- STING enhances cell death through regulation of reactive oxygen species and DNA damage (2021) (30)
- Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival (2017) (30)
- Comparison of Survival Outcomes Among Human Papillomavirus–Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study (2017) (30)
- LBA31A PHASE IB STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH HUMAN PAPIILLOMA VIRUS (HPV)-POSITIVE AND NEGATIVE HEAD AND NECK CANCER (HNC) (2014) (30)
- Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. (2013) (30)
- Predicting survival in head and neck squamous cell carcinoma from TP53 mutation (2015) (28)
- Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. (2005) (28)
- E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC). (2013) (28)
- Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience (2001) (27)
- KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer. (2015) (26)
- Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers (2013) (26)
- PET/CT radiomics signature of human papilloma virus association in oropharyngeal squamous cell carcinoma (2020) (25)
- Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score (2022) (25)
- Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial (2014) (25)
- PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. (2019) (25)
- ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). (2012) (25)
- Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. (2020) (25)
- Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma (2012) (24)
- A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study (2012) (24)
- Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. (2019) (24)
- Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck. (2005) (24)
- A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. (2014) (24)
- Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. (2018) (24)
- A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. (2020) (24)
- Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer (2000) (23)
- Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? (2019) (23)
- Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell Carcinoma (2020) (22)
- High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. (1998) (22)
- Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation (2005) (22)
- Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment. (2017) (22)
- Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial (2000) (22)
- Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer (2007) (22)
- Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. (2009) (21)
- Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer (2002) (21)
- A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study. (2006) (21)
- Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). (2010) (20)
- Bimodal population or pathologist artifact? (2007) (20)
- Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (2018) (20)
- National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database (2015) (20)
- Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590) (2017) (20)
- Oropharyngeal squamous cell carcinoma treatment: current standards and future directions (2014) (20)
- Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). (2013) (19)
- Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma (2022) (19)
- Mucosal melanoma of the head and neck. (2012) (19)
- Biomarker driven treatment of head and neck squamous cell cancer (2017) (19)
- Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment (2019) (18)
- Head and neck cancers. (2011) (18)
- Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck (2017) (18)
- Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies (2002) (18)
- Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck (2015) (18)
- Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma (2019) (18)
- Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling (2019) (17)
- Quality of Life With Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. (2020) (17)
- Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers. (2019) (17)
- Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study (2021) (17)
- Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment. (2019) (16)
- Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology (2007) (16)
- Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting (2010) (16)
- Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311). (2021) (16)
- Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling” (2012) (16)
- Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. (2016) (16)
- Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer (2020) (16)
- Her signaling in pancreatic cancer (2007) (15)
- Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1). (2015) (15)
- Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19–9 results (2008) (15)
- KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (2020) (15)
- Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. (2019) (15)
- Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040. (2018) (15)
- A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells (1999) (14)
- A preclinical xenotransplantation animal model to assess human hematopoietic stem cell engraftment (2004) (14)
- EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN) (2007) (14)
- KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). (2017) (13)
- National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation. (2018) (13)
- Informational needs of head and neck cancer patients (2012) (13)
- Prediction of post-radiotherapy locoregional progression in HPV-associated oropharyngeal squamous cell carcinoma using machine-learning analysis of baseline PET/CT radiomics (2020) (13)
- Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis (2020) (13)
- Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study (2022) (13)
- Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations (2018) (13)
- Cetuximab-Associated Acneiform Eruption (2005) (12)
- Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer (2016) (12)
- LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). (2017) (12)
- A randomized phase II study of BMS-247550 (ixabepilone) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck. (2006) (11)
- Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report (2020) (11)
- Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer. (2022) (11)
- The maximum negative binomial distribution (2000) (11)
- Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation (2021) (11)
- Predictive classifier for intensive treatment of head and neck cancer (2020) (10)
- E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process. (2016) (10)
- Esophageal carcinoma: are modern targeted therapies shaking the rock? (2013) (10)
- Pretreatment predictors of adjuvant chemoradiation in patients receiving transoral robotic surgery for squamous cell carcinoma of the oropharynx: a case control study (2016) (10)
- Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns (2013) (10)
- Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. (2017) (10)
- Association of epigenetic age acceleration with risk factors, survival, and quality of life in patients with head and neck cancer. (2021) (9)
- Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer (2020) (9)
- Correlation of tumor mutational burden (TMB) with CDKN2A and TP53 mutation in HPV-negative head and neck squamous cell carcinoma (HNSCC). (2020) (9)
- Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy (2018) (9)
- Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer (2015) (9)
- 71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results (2020) (9)
- Head and Neck Cancer (2010) (9)
- Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer. (2009) (9)
- Improved method for the detection of cytokeratin 19-positive cells in the peripheral blood of breast cancer patients (2004) (9)
- Survivin expression and impact on head and neck cancer outcomes. (2020) (9)
- Multi-Modality Therapy for Cancer of the Esophagus and GE Junction (2012) (8)
- LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients. (2012) (8)
- Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer (2013) (8)
- Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer (2005) (8)
- Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (2020) (8)
- Phosphorylation of Akt ( Ser 473 ) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer (2007) (8)
- Molecular Determinants of Head and Neck Cancer (2018) (8)
- LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) (2022) (8)
- Activity of cetuximab (C) in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C. (2013) (8)
- The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function (2000) (8)
- Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial. (2018) (8)
- Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer. (2004) (8)
- EGFR-directed antibodies increase the risk of severe infection in cancer patients (2015) (8)
- Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS V2). (2015) (8)
- 11TiPPhase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048 (2015) (8)
- HPV Association and the Increasing Incidence of Unknown Primary Head-and-Neck Squamous Cell Carcinoma : Epidemiology and Prevention (2014) (7)
- Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy (2019) (7)
- Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. (1999) (7)
- IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC. (2017) (7)
- Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials (2006) (7)
- Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. (2022) (7)
- New directions in perioperative management of locally advanced esophagogastric cancer. (2014) (7)
- EGFR and RB 1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer (2016) (7)
- Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience (2011) (6)
- E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. (2014) (6)
- Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials. (2017) (6)
- A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. (2000) (6)
- Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma (2019) (6)
- Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. (2019) (6)
- Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. (2022) (6)
- A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/ metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201. (2017) (6)
- Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study. (2018) (6)
- The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation. (2017) (6)
- Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer (2014) (6)
- 915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (2020) (5)
- Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (2018) (5)
- Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection (2017) (5)
- Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. (2018) (5)
- KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC). (2018) (5)
- Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer (2004) (5)
- 2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012 (2015) (5)
- Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). (2015) (5)
- Overview: The Pathobiology of Head and Neck Cancer (2014) (5)
- Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma (HNSCC) from KEYNOTE-040 (2019) (5)
- Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck. (2016) (4)
- Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. (2022) (4)
- Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable? (2021) (4)
- Assessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies. (2017) (4)
- Abstract P078: Aurora A kinase inhibition with VIC-1911 overcomes intrinsic and acquired resistance to KRASG12C inhibition in KRAS(G12C)-mutated lung cancer (2021) (4)
- Further clinical interpretation and implications of KEYNOTE-048 findings – Authors' reply (2020) (4)
- ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer (2020) (4)
- Targeted therapies: Molecular selection for 'smart' study design in lung cancer (2010) (4)
- Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer. (2014) (4)
- 632 POSTER Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301 (2006) (4)
- Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients (2005) (3)
- Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303). (2010) (3)
- Abstract2111: ECOG 1200: A Randomized Phase II Trial of Gemcitabine Plus Radiotherapy vs Gemcitabine, 5-Fluorouracil and Cisplatin Followed by Radiotherapy and 5-Fluorouracil in Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma (2006) (3)
- Weekly chemotherapy with irinotecan plus a taxane in advanced non small cell lung cancer (NSCLC) (2000) (3)
- Radiologist-oncologist workflow analysis in application of RECIST (2008) (3)
- Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck. (2017) (3)
- A phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction. (2012) (3)
- Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC). (2016) (3)
- Moving Forward in the Management of Squamous Cell Carcinoma of the Head and Neck: Promising Immuno-Oncology Approaches (2015) (3)
- p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC). (2011) (3)
- Sequential High‐Dose Alkylating Therapy and Stem Cell Support for High‐Risk Stage III Breast Cancer (2003) (3)
- AbstractDoxorubicin induced congestive heart failure: Decreasing incidence with routine use of radionuclide angiocardiography (1999) (3)
- Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404) (2022) (3)
- Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). (2021) (3)
- Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA. (2010) (3)
- Gene expression differences associated with silencing of E6 and E7 viral oncogenes in HPV16+ oropharyngeal cancer cell lines (2008) (3)
- Oropharyngeal cancer. (2008) (3)
- p16 Status, Pathologic and Clinical Characteristics, and Long-term Outcomes in Unknown Primary Carcinomas of the Head and Neck (2012) (3)
- Biologically based treatment in head and neck squamous cell carcinoma (HNSCC) (2012) (3)
- Targeted agents: management of dermatologic toxicities. (2014) (3)
- TRAF3 and CYLD Gene Defects in HPV-Associated Head and Neck Cancer: Biomarker of Response and Indicator of Targets for New Therapies (2018) (2)
- Commentary: bevacizumab and erlotinib with chemoradiation for head and neck cancer. (2011) (2)
- Antibody-Based Therapies for Solid Tumors (2011) (2)
- Ceritinib in anaplastic thyroid cancer (ATC) with ALK abnormalities. (2015) (2)
- Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors (2019) (2)
- The tumor genome in human immunodeficiency virus–related head and neck cancer: Exploitable targets? (2018) (2)
- Successful Identification of Head and Neck Cancer (HNC) Nodal Metastasis (NM) and Extranodal Extension (ENE) Using Deep Learning Neural Networks (2018) (2)
- Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. (2013) (2)
- The role and targeting of Aurora kinases in head and neck cancer (2014) (2)
- Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040 (2021) (2)
- Abstract 721: Expression of Aurora A and Phospho-Aurora-A is predictive of survival in patients with head and neck cancer (2012) (2)
- Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer. (2007) (2)
- Regulation of cytoplasmic and nuclear PTEN levels by human papillomavirus (HPV) type 16 E6 and E7 oncogenes in HPV16+ oropharyngeal cancer cell line (2008) (2)
- Treatment De-Intensification for Locally Advanced HPV-Associated Oropharyngeal Cancer (2015) (2)
- Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients (2022) (2)
- Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. (2010) (2)
- Novel targets in pancreatic cancer: focus on future paths to therapy (2006) (2)
- Guideline - Adherence in advanced stage head and neck cancer is associated with improved survival - A National study. (2021) (2)
- Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer. (2004) (2)
- Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state. (2019) (2)
- Mucosal Melanoma of the Head and Neck Clinical Practice Guidelines in Oncology (2012) (2)
- Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC). (2017) (2)
- Viruses in head and neck cancers: prevention and therapy (2008) (2)
- 658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040 (2022) (2)
- PTEN loss as a predictive biomarker in head and neck squamous cell cancer (HNSCC) patients treated with cetuximab (C). (2017) (2)
- SU‐GG‐T‐178: Intensity‐Modulated Radiation Therapy (IMRT) in the Treatment of Oropharyngeal Carcinoma: Clinical Outcomes and Relation of Parotid Gland Volume with Xerostomia (2010) (2)
- Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1) (2016) (2)
- Images in clinical medicine. Cetuximab-associated acneiform eruption. (2005) (2)
- Low Rates of Gastrostomy Tube Dependence in Patients with T1-T2 Oropharynx Cancer Treated without Pharyngeal Constrictor Sparing (2011) (2)
- Correlates and determinants of nuclear epidermal growth factor receptor (EGFR) content in an oropharyngeal cancer tissue microarray (2007) (2)
- Gene copy number of epidermal growth factor receptor (EGFR) by fluorescent in situ hybridization (FISH) in head and neck squamous cell carcinomas (HNSCC) is closely correlated with EGFR protein levels assessed by automated quantitative protein analysis (AQUA) (2007) (1)
- Predictive Biomarkers and Personalized Medicine Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC : Eastern Cooperative Oncology Group E 2303 (2014) (1)
- Dysplasia at the Margin? Investigating the Case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue (2012) (1)
- Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck (2020) (1)
- Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer (2022) (1)
- Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck. (2013) (1)
- Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. (2020) (1)
- Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (2017) (1)
- A 30-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (2014) (1)
- P53 in Head and Neck Squamous Cell Carcinoma (2018) (1)
- Integrating Targeted Therapies in the Management of Head and Neck Cancers. (2022) (1)
- Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC). (2012) (1)
- Abstract 714: Survivin expression in patients with resected pancreatic adenocarcinoma (2012) (1)
- TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC). (2021) (1)
- 438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer (2021) (1)
- Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study. (2013) (1)
- Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients. (2021) (1)
- The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss. (2022) (1)
- Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer (2010) (1)
- Phase I clinical trials of intravenous 2′-deoxycytidine-2′-fluoromethylene (FMdC) in patients with advanced solid tumors (1999) (1)
- Complexity in the Gastric Cancer Genome and a Biomarker-Driven Trial of Poly (ADP-Ribose) Polymerase Inhibition in Gastric Cancer. (2015) (1)
- Analysis of epidermal growth factor receptor (EGFR) pathway in oropharyngeal squamous cell cancer patients in vivo (OSCC) (2005) (1)
- Predictor of effectiveness of treatment intensification on overall survival in head and neck cancer (HNC). (2018) (1)
- Effect of increased time from chemoradiation to surgery on the pathologic complete response rate in patients with esophageal cancer. (2012) (1)
- Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma. (2017) (1)
- A 3 0-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and / or metastatic head and neck squamous cell carcinoma (2014) (1)
- Reply to A. Garden et al. (2017) (1)
- Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma (2023) (1)
- Evaluation of the prognostic significance of activated STAT3 expression levels in head and neck squamous cell carcinoma (HNSCC) (2008) (1)
- Molecular pro fi le of head and neck squamous cell carcinomas bearing p 16 high phenotype (2013) (1)
- Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs. (2021) (1)
- High Dose Cisplatin: Still the One? (2020) (1)
- P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 (2021) (1)
- NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer (2022) (1)
- Abstract 604: Combination of the Aurora A inhibitor TAS-119 and adavosertib results in synergistic c-Jun-mediated cell death in head and neck and lung cancers (2020) (1)
- 13TiPPembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized trial (2015) (1)
- Phase 1/2 study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer (2015) (1)
- MA02.07 Aurora A Kinase Inhibition with VIC-1911Potentiates KRASG12C Inhibitor and Overcomes Resistance to Sotorasib in Lung Cancer (2022) (1)
- SU‐GG‐T‐180: Intensity‐Modulated Radiation Therapy (IMRT) for the Para‐Nasal Sinus (PNS) Malignancies: Outcomes from Fox Chase Cancer Center (FCCC) (2010) (1)
- TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer. (2021) (1)
- 351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 (2020) (1)
- Combination of WEE1 and AURKA inhibition in HPV negative head and neck squamous cell carcinoma. (2017) (1)
- Reply to "Keynote 48: Is it really for everyone?" (2020) (1)
- Surgical treatment of esophageal cancer. (2003) (1)
- 314O_PRSecond-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1) (2015) (1)
- Initial Results of a Phase I Dose Escalation Trial of Concurrent and Maintenance Erlotinib and Re-ir (2009) (1)
- Preoperative chemoradiation for esophageal cancer. (1999) (1)
- Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update (2023) (1)
- Survival Outcomes Among Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Patients Treated with Upfront Surgery Versus Definitive Chemoradiation Therapy (2017) (1)
- 354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer (2020) (1)
- 1105TiPPembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial (2017) (0)
- Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition (2019) (0)
- Intensity Modulated Radiation Therapy (IMRT) for the Para-nasal Sinus (PNS) Malignancies (2010) (0)
- Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype. (2009) (0)
- Journal Online (2017) (0)
- First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened? (2023) (0)
- (S040) The Risk of Level IB Nodal Involvement in Oropharynx Cancer: Guidance for Submandibular Gland Sparing Irradiation (2017) (0)
- Predictive Biomarkers and Personalized Medicine Quanti fi cation of Excision Repair Cross-Complementing Group 1 and Survival in p 16-Negative Squamous Cell Head and Neck Cancers (2013) (0)
- Improving Diversity, Equity, and Inclusion Education in Hematology/Oncology Training (2022) (0)
- Evaluating the Medical Management of Locally Advanced and Metastatic Basal Cell Carcinoma: A Single Institutional Retrospective Analysis Investigating Efficacy, Safety, and Tolerability (2023) (0)
- Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC). (2006) (0)
- Devising novel imaging biomarkers for Human Papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC): applying radiomics and machine learning algorithms (2020) (0)
- Abstract LB-178: Genomic analysis identifies a subset of laryngeal tumors with poor prognosis (2015) (0)
- Abstract C172: Concomitant disruption of WEE1 and AurKA synergistically enhances anti-cancer effects in p53 mutated head and neck squamous cell carcinoma (2015) (0)
- 445 Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer (2013) (0)
- Phase I I E valuation o f P reoperative C hemoradiation a nd Postoperative A djuvant C hemotherapy f or S quamous C ell and A denocarcinoma o f t he E sophagus (2000) (0)
- Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. (2023) (0)
- Abstract 2804: ERCC1 (excision repair cross complementing group 1) is a predictive biomarker of survival in squamous cell carcinoma of the head and neck (SCCHN) (2010) (0)
- Fatty acid desaturase specificity in tetrahymena (1984) (0)
- Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks (2018) (0)
- Abstract 542: Synthetic lethal targeting of AURKA in head and neck squamous cell carcinoma (2023) (0)
- Outcomes stratification of head and neck cancer using pre- and post-treatment DNA methylation from peripheral blood. (2022) (0)
- Abstract 4732: Analysis of KRAS variant in a cohort of resected HPV negative HNSCC (2017) (0)
- Informational needs of head and neck cancer patients (2012) (0)
- Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84). (2022) (0)
- Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. (2023) (0)
- Abstract IA17: Treatment de-intensification strategies for head and neck cancer (2017) (0)
- Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590). (2016) (0)
- 2036 The natural history of local regional breast cancer recurrence: Prognosis and implications for systemic therapy (1997) (0)
- Phase 1/2 Study of Pepinemab in Combination with Pembrolizumab as First-Line Treatment of Advanced, Recurrent or Metastatic Head and Neck Cancer (KEYNOTE B84) (2022) (0)
- Phase II study of pemetrexed (P) and gemcitabine (G) in patients with advanced head and neck cancer (SCCHN). (2009) (0)
- Evaluation of computational tools to determine prognostic significance of TP53 mutation in head and neck squamous cell carcinoma (HNSCC). (2014) (0)
- Histologic markers and long-term prognosis in breast cancer. (1997) (0)
- (S027) Hypofractionated Radiotherapy Is associated With Improved Overall Survival Among Patients With Early-Stage Glottic Cancer (2017) (0)
- 246 INVITED Targeting Her: Can resistance to EGFR inhibitors be overcome? (2008) (0)
- 373TiPKEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (2017) (0)
- Principles of Cancer Therapy (2010) (0)
- 133 Spatially defined gene signatures uncover the association of extracellular matrix genes with immunotherapy resistance in head and neck squamous cell carcinoma (2022) (0)
- Abstract A126: Analysis of excision repair cross complementing group 1 (ERCC1) expression in squamous cell carcinoma of the head and neck (SCCHN) (2009) (0)
- Can It Stay or Should It Go? A Comparison of T4 Laryngeal Cancer Management (2013) (0)
- Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. (2022) (0)
- Abstract 4743: Analysis of a protein expression biomarkers in HPV negative SCCHN (2014) (0)
- Abstract 1563: Concomitant inhibition of Aurora kinase A and WEE1 kinases results in synergistic tumor control and heightens DNA replication stress in head and neck and lung carcinomas (2023) (0)
- Assessment of phosphatidylinositol-3 kinase (PI3K) as a prognostic marker in head and neck squamous cell carcinoma (HNSCC). (2016) (0)
- Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases (2022) (0)
- The use of a Low Neck Field (LNF) and Intensity-Modulated Radiation Therapy (IMRT): No Clinical Detr (2009) (0)
- Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. (2023) (0)
- Trials and tribulations: Clinical trials and the future (2020) (0)
- Immunotherapy of Head and Neck Cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 9-10, 2014, Bethesda, Maryland (2016) (0)
- Maximizing the Effect of Neoadjuvant Chemoradiation in Patients with Borderline Resectable Pancreatic Cancer (2011) (0)
- Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastases. (2006) (0)
- High-dose chemotherapy for the treatment of high-risk and advanced breast cancer. (1999) (0)
- Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification. (2017) (0)
- Quantitative immunohistochemical analysis of VEGF expression on a pancreatic cancer tissue microarray (2004) (0)
- Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer (2017) (0)
- Hypoxia-Guided Therapy for Human Papillomavirus-Associated Oropharynx Cancer. (2021) (0)
- Adjuvant External Beam Radiation Therapy for Surgically Resected, Non-Metastatic Anaplastic Thyroid Cancer (2018) (0)
- ERCC1 and RRM1 expression in resected pancreatic adenocarcinoma. (2011) (0)
- Reducing Treatment Doses in Head and Neck Cancer to Improve QOL (2017) (0)
- Cancer Biology and Etiologic Factors (2010) (0)
- 973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (2020) (0)
- Docetaxel and irinotecan combination chemotherapy in advanced esophageal cancer (2010) (0)
- 27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target (2023) (0)
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 (2018) (0)
- Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy (2022) (0)
- Screening for Extranodal Extension with Deep Learning: Evaluation in ECOG-ACRIN E3311, a Randomized De-Escalation Trial for HPV-Associated Oropharyngeal Carcinoma (2022) (0)
- SP-012 Pembrolizumab in the first line treatment of recurrent and/or metastatic head and neck cancer (2019) (0)
- Introducing cancers of the head and neck, a new open access journal (2016) (0)
- Immunotherapy Trials in Head and Neck Cancer (2017) (0)
- Strategies to Optimize EGFR Therapies (2012) (0)
- Predictive Molecular Biomarkers for HPV-Associated Head and Neck Squamous Cell Carcinoma (2022) (0)
- Predictive biomarkers in a phase II trial of weekly carboplatin (CBDCA), paclitaxel (P), and cetuximab (C) induction and chemoradiation (CRT) in patients (pts) with resectable stage III/IVa,b head and neck squamous cell carcinoma (HNSCC): Eastern Cooperative Oncology Group E2303. (2013) (0)
- Abstract CT109: First-in-class first-in-human phase 1 trial and translational study of the mono(ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors (2023) (0)
- 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048 (2022) (0)
- Evaluation of Primary Treatment Technique for Squamous Cell Carcinoma of the Buccal Mucosa: A Single-Center Experience (2014) (0)
- P-88 First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study (2021) (0)
- External Validation and Radiologist Comparison of a Deep Learning Model (DLM) to Identify Extranodal Extension (ENE) in Head and Neck Squamous Cell Carcinoma (HNSCC) with Pretreatment Computed Tomography (CT) Imaging (2019) (0)
- Author Correction: Head and neck squamous cell carcinoma (2023) (0)
- 1050PD Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naı̈ve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) (2018) (0)
- Lead Authors and Contributors (2010) (0)
- Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-Treatment DNA Methylation in Peripheral Blood. (2021) (0)
- Oropharyngeal Cancer: HPV-Positive Disease (2018) (0)
- E2399: Correlation of objective and self report measures of swallowing function after concurrent chemoradiation (CCR) for head and neck cancer (HNC) (2008) (0)
- Reduced Aspiration Rates for 50 Gy Postoperative Radiation in HPV-Associated Oropharynx Cancer in E3311: A Trial of the ECOG-ACRIN Cancer Research Group (2022) (0)
- NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis (2017) (0)
- 83 Long term local control and survival with preoperative cisplatin, continuous infusion 5-FU, and 45 Gy radiotherapy for esophageal cancer (1999) (0)
- Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (2020) (0)
- Evaluation of Pathology-Based Staging for HPV-Associated Squamous Cell Carcinoma of the Oropharynx in a Large National Sample (2017) (0)
- Assessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and Neck (2020) (0)
- Abstract IA20: Radiotherapy plus cetuximab or cisplatin in human papilloma-virus positive oropharyngeal cancer (NRG 1016): A randomized multicenter noninferiority trial* (2020) (0)
- Head and Neck CancersPractice Guidelines in Oncology (2011) (0)
- The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss. (2010) (0)
- Role for Afatinib in p16-Negative Head and Neck Cancer? (2017) (0)
- Projections: Novel Therapies for HPV-Negative Cancers of the Head and Neck (2014) (0)
- Abstract 2254: Nuclear and cytoplasmic epidermal growth factor receptor and p16 expression as prognostic biomarkers in head and neck squamous cell carcinoma (2011) (0)
- Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs (2019) (0)
- SP-046: For the motion (2015) (0)
- Top advances of the year: Head and neck cancer (2023) (0)
- On mentorship: lessons from my father. (2014) (0)
- Predicting survival in head and neck squamous cell carcinoma from TP53 mutation (2014) (0)
- 681 A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer (2022) (0)
- Transplantation Hematopoietic Cells: A Potential Purging Method for Autologous Reduce Breast Cancer Cells 1 Million-Fold When They Contaminate Cytosine Deaminase Adenoviral Vector and 5-Fluorocytosine Selectively (2013) (0)
- Abstract 5814: Synthetic lethal therapy to overcome resistance to AURKA inhibition in HPV-negative head and neck cancer (2018) (0)
- Molecular prognostic markers in squamous cell carcinoma of the head and neck: the role of E-cadherin (2008) (0)
- Targeting the ErbB Family in Head and Neck Cancer (2018) (0)
- Comparison of Upfront Surgery Versus Chemoradiation for cT1-2 N1-2b Oropharynx Squamous Cell Carcinoma Based on Human Papillomavirus Status (2016) (0)
- Abstract CT111: Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE B84) (2022) (0)
- Advanced gastric cancer: new treatments raise new questions. (2008) (0)
- Methodologic Concerns in Secondary Analysis of KEYNOTE-048. (2022) (0)
- Chapter 23 – Neoplastic Diseases (2004) (0)
- Devising novel imaging biomarkers for Human Papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC): applying radiomics and machine learning algorithms (2020) (0)
- Imaging, Diagnosis, Prognosis Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma (2011) (0)
This paper list is powered by the following services:
Other Resources About Barbara Burtness
What Schools Are Affiliated With Barbara Burtness?
Barbara Burtness is affiliated with the following schools:
